Zomagen Biosciences Ltd, a wholly owned subsidiary of Ventyx Biosciences (VTYX), received FDA orphan designation for a treatment of pericarditis, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Largest borrow rate increases among liquid names
- Ventyx Biosciences Sets March 3, 2026 Vote on Eli Lilly $14-Per-Share Cash Merger
- Ventyx Biosciences call volume above normal and directionally bullish
- Ventyx Biosciences Sets Special Cash Bonuses Amid Lilly Merger
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!